(which correspond to 39, 78, 117, 156, and 234 mg of paliperidone palmitate) respectively (ie 25‐fold dose conversion factor from oral risperidone to PP1M. Conclusions This study provides clinicians with a practical guidance to establish suitable maintenance dose levels of PP1M and oral ...